Literature DB >> 15384126

Impact of the motor complications of Parkinson's disease on the quality of life.

Stéphane Chapuis1, Lemlih Ouchchane, Olivier Metz, Laurent Gerbaud, Franck Durif.   

Abstract

The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IV(A) and IV(B) and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients. Copyright 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15384126     DOI: 10.1002/mds.20279

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  134 in total

Review 1.  [Deep brain stimulation for Parkinson's disease].

Authors:  J Herzog; G Deuschl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 2.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

Review 3.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

4.  Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Authors:  Cicely Kerr; Emily J Lloyd; Charlotte E Kosmas; Helen T Smith; James A Cooper; Karissa Johnston; Emma McIntosh; Andrew J Lloyd
Journal:  Qual Life Res       Date:  2015-12-01       Impact factor: 4.147

5.  Health-related quality of life of australians with Parkinson disease: a comparison with international studies.

Authors:  Sze-Ee Soh; Jennifer L McGinley; Jennifer J Watts; Robert Iansek; Meg E Morris
Journal:  Physiother Can       Date:  2012       Impact factor: 1.037

Review 6.  Stem cell transplantation: a promising therapy for Parkinson's disease.

Authors:  Yi Wang; Sheng Chen; Dehua Yang; Wei-dong Le
Journal:  J Neuroimmune Pharmacol       Date:  2007-05-09       Impact factor: 4.147

7.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Authors:  Rosella Ciurleo; Francesco Corallo; Lilla Bonanno; Viviana Lo Buono; Giuseppe Di Lorenzo; Roberta Versaci; Cettina Allone; Rosanna Palmeri; Placido Bramanti; Silvia Marino
Journal:  J Neurol       Date:  2018-06-27       Impact factor: 4.849

Review 8.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

9.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

Review 10.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.